LLY — Eli Lilly and Company

As of 2026-08-27, the tape is constructive but not euphoric: LLY is down 1.2% on the day to $1,175.49, but Q2 2026 revenue of $22.97B (+47.7% YoY) and non-GAAP EPS of $8.38 beat consensus by roughly 27%, management lifted FY2026 revenue guidance to $85-87B and EPS to ~$36.00, and the analyst consensus is Buy with an average target of $1,341.63. The 45.6 RSI and nearness to the 50-day SMA show the market is absorbing the run rather than chasing it.

Revenue has accelerated from $9.3-9.5B per quarter in late-2023 to $17.6B in Q3 2025, $19.3B in Q4 2025, $19.8B in Q1 2026 and $23.0B in Q2 2026; YoY growth has been in the 42-56% range for the past five quarters. Operating margin has moved from the mid-30s in 2023 to the mid-to-high 40s in 2025/2026, with Q2 2026's dip to 39.1% reflecting higher R&D and one-off charges rather than a broken trend. Net income swung from a small loss in Q3 2023 to $7.1B in Q2 2026, and TTM free cash flow is about $20B after multiple negative quarters in 2023-2024. This is a structurally accelerating growth story, not a one-quarter blip.

As of 2026-08-27, LLY is not cheap in absolute terms - 39.4x trailing EPS, roughly 32.3x forward FY2026 EPS of $36.40, 13.9x sales and 31x book value - but it is cheap relative to its own 5-year average P/E of 63.1 and roughly in line with its 5-year average P/S of 13.4. Given 84% gross margins, ~30% ROIC and 47.7% revenue growth, a 32x forward multiple is reasonable; the stock looks fairly valued with a slight growth-driven bargain tilt versus its own history.

The price has not kept up with the earnings surge: the market cap is far higher, but the P/E has compressed from a 63x 5-year average to 39x trailing while estimates keep moving up. As of 2026-08-27, the stock is pricing in continued strong execution - roughly $36 EPS this year and another leg from retatrutide/orforglipron later - but not perfection. If guidance rises again or retatrutide hits, the stock can re-rate toward the $1,341-1,355 analyst target zone; if competition or pricing pressure bites, the 32x forward multiple offers only a moderate cushion.

On 2026-08-27, RSI was 45.6 - neutral, not oversold - and LLY was 2.1% below its 20-day SMA and 0.9% below its 50-day SMA, while still 11.0% above its 200-day SMA. That is a consolidation/range-bound pattern within a broader uptrend, with support near the 200-day (roughly $1,059) and resistance near the 52-week high of $1,292.65. It suggests no urgency to chase here; a pullback toward the 50-day/200-day zone would offer better risk/reward.

• GLP-1/obesity market expansion toward $100B-$200B by industry trackers, with Lilly and Novo Nordisk as the entrenched duopoly.
• Medicare GLP-1 Bridge program, rolled out in mid-2026, improving U.S. payer access and prescription volumes for Zepbound/Mounjaro.
• Net realized price pressure: Q2 2026 net prices ex-rebate fell about 13% on volume scaling and international formulary constraints such as China's NRDL, a structural headwind to revenue per script.
• Regulatory and legal environment: FDA cleared the Lilly/Roche Alzheimer's blood test, and Lilly's lawsuits against compounding pharmacies and black-market peptides could protect the franchise but add legal uncertainty.
• Large-cap healthcare as defensive growth: low beta of 0.51 and a $1.1T market cap make LLY a portfolio anchor, though broad rate and multiple shifts can still hit the stock.

• Retatrutide (triple-agonist GIP/GLP-1/glucagon) Phase 3 data and a BLA filing anticipated around Q1 2027, with near-bariatric-surgery efficacy potential.
• Orforglipron oral GLP-1 progress and global regulatory milestones.
• Continued Mounjaro/Zepbound global launches, additional indications, real-world cost-effectiveness data, and Medicare Bridge-driven volume growth.
• Competitive readouts from Novo Nordisk, Roche, and AstraZeneca in H2 2026 could either validate or challenge Lilly's efficacy lead.

• Pricing pressure and rebates: realized net price ex-rebate already fell ~13% in Q2 2026, and international pricing constraints could keep cutting revenue per patient.
• Competitive threat: Novo, Roche, AstraZeneca and others are targeting the same obesity/diabetes market; a head-to-head efficacy or safety win against Lilly would hit the multiple hard.
• Clinical/regulatory setbacks: retatrutide or orforglipron failure or delay would remove the next leg of growth optionality.
• High expectations and balance-sheet leverage: forward P/E is still ~32x, debt-to-equity is 1.62, and IPR&D/one-off charges ($2.78B in recent quarters) can create noisy EPS and cash-flow swings.

Eli Lilly is a rare mega-cap with genuine accelerating growth: 47.7% revenue growth, 84% gross margin, roughly 30% ROIC, and a pipeline that could extend the incretin franchise for another decade. At 32x forward earnings as of 2026-08-27 with estimates still rising, I lean bullish - not a low-risk value stock, but a high-quality compounder where the market is paying up for growth that is actually showing up in the numbers.

Calculated by applying a 36.5x forward P/E to FY2026 consensus EPS of $36.40. The multiple is a compromise: a premium to the current 32.3x forward P/E to reflect 47.7% revenue growth, 84% gross margin and ~30% ROIC, but well below LLY's 5-year average P/E of 63x because that average was distorted by a much lower earnings base. This yields $1,328.42, roughly 13% above the 2026-08-27 price.